Robert L Coleman, MD: The Society of Gynecologic Oncology, The American Society of Clinical Oncology, and our European colleagues have all recommended that a patient who has a suspected diagnosis of ovarian cancer should be seen by a gynecologic oncologist. There’s many reasons for this. One is that the gynecologic oncologist brings a surgical perspective into the picture. Patients who are newly diagnosed should have an adequate assessment of whether or not surgery is indicated. Some of this has to do with different healthcare systems around the globe. But we’re seeing that there is, often times, either the inability or the unfamiliarity of the importance of surgery in primary ovarian cancer treatment. Then, patients are triaged to neoadjuvant chemotherapy.
As part of the treatment team, even if a gynecologic oncologist isn’t going to be administering the chemotherapy after surgery, or at any point down the line, it’s important that there be an appropriate surgical consultation before the patient starts a chemotherapy strategy.
It’s important to have gynecologic oncology representation as part of the team that looks at the data that would support using or bringing new therapies, as they arise out of our clinical trials, to the formulary, or to the hospital, or to the clinic. We conduct these large trials as a cooperative group, in most cases. Or, we conduct them along with industry to help identify the right patients under the right circumstances for the right duration of treatment. I think that the gynecologic oncologists, many of whom have participated in these trials extensively, can bring the understanding of that to the group. That expertise is really vital to understanding where these new compounds should be positioned and how they should be delivered.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More